Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium-Reference-Cited by-同舟云学术

Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium

Published:2022-10-31 Issue:3 Volume:30 Page:1485-1494
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ogobuiro Ifeanyichukwu,Collier Amber L.,Khan Khadeja,de Castro Silva Iago,Kwon Deukwoo,Wilson Gregory C.,Schwartz Patrick B.,Parikh Alexander A.,Hammill Chet,Kim Hong J.,Kooby David A.,Abbott Daniel,Maithel Shishir K.,Snyder Rebecca A.,Ahmad Syed A.,Merchant Nipun B.,Datta Jashodeep^ORCID

Funder

National Cancer Institute

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-12741-4.pdf

Reference36 articles.

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.

2. Tesfaye AA, Philip PA. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. Clin Adv Hematol Oncol. 2019;17(1):54–63.